Clinical trials: Primary Headache Disorders
Migraine Headache
Safety and Tolerability of POD-DHE (INP104) in Migraine (STOP 301)
This study consists of a 4-week screening period, a 24-week treatment period for all participants, followed by a 28-week treatment period extension (to 52 weeks in total) for a subset of at least 60 and up to 80 participants, and…
- Trial name
- NCT03557333
- Testing
- INP104
- Where
- 36 sites in United States
- Volunteers
- 360 people
- Sponsor
- Impel Pharmaceuticals
Migraine
Safety, Tolerability and Drug- Drug Interaction Study of Ubrogepant With Erenumab or Galcanezumab in Participants With Migraine
This study will evaluate the potential for a pharmacokinetic (PK) interaction and provide safety and tolerability information when ubrogepant and erenumab or ubrogepant and galcanezumab are co-administered.
- Trial name
- NCT04179474
- Testing
- Ubrogepant, Erenumab, Galcanezumab
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Allergan
Migraine Disorders
Treximet ™ Pharmacy Budget Impact Model Database Validation Study
The purpose of this retrospective claims database study was to compare the change in migraine-related prescription (i.e. NSAIDs, Opioids, Ergots) utilization among migraine suffers following initiation of Treximet ™…
- Trial name
- NCT01332500
- Testing
- Sumatriptan/Naproxen combination, other oral triptans
- Volunteers
- 61,737 people
- Sponsor
- GlaxoSmithKline
Migraine
Study of EVO756 in Adults With Migraine
This study will evaluate the efficacy and safety of EVO756 against placebo in adults with migraine.
- Trial name
- NCT07616128
- Testing
- EVO756, Dose 1, EVO756, Dose 2
- Where
- 45 sites in United States, Australia and 2 more
- Volunteers
- 330 people
- Sponsor
- Evommune, Inc.
High Frequency, High Disability Migraine
Pathway M-1: Sphenopalatine Ganglion Stimulation for the AcuteTreatment of High Disability Migraine Headache
The purpose of the clinical study is to evaluate the use of an implanted sphenopalatine ganglion (SPG) neurostimulator for the treatment of migraine headache pain, migraine headache symptoms and migraine frequency in high…
- Trial name
- Pathway M-1 (NCT01540799)
- Testing
- ATI Neurostimulation System
- Where
- 3 sites in Belgium, Denmark and 1 more
- Volunteers
- 80 people
- Sponsor
- Autonomic Technologies, Inc.
Migraine Headache
A Study of Galcanezumab (LY2951742) in Participants With Migraine Headache
The main purpose of this study is to evaluate whether the study drug known as galcanezumab is safe and effective in the prevention of migraine headaches.
- Trial name
- NCT02163993
- Testing
- Galcanezumab
- Where
- 40 sites in United States
- Volunteers
- 414 people
- Sponsor
- Eli Lilly and Company
Migraine
A Proof of Concept Alleviating the Symptoms of Photosensitive Migraine.
This proof of concept clinical study will investigate the efficacy of active lens with frame in alleviating the symptoms of migraine which are caused by photosensitivity.
- Trial name
- NCT04904328
- Testing
- Lumishade® Active Lens
- Volunteers
- 77 people
- Sponsor
- Mitsui Chemicals, Inc.
Migraine Headache
Treatment of Multiple Attacks of Acute Migraine (0462-025)
A study to evaluate rizatriptan for the treatment of multiple attacks of acute migraine compared to placebo.
- Trial name
- NCT00899379
- Testing
- rizatriptan benzoate
- Volunteers
- 473 people
- Sponsor
- Organon and Co
Migraine, Headache
Efficacy and Safety of a Fixed-dose Combination of Naratriptan and Naproxen in Acute Treatment of Migraine
The purpose of this study is to determine whether a fixed-dose combination of naratriptan + naproxen is effective compared each monotherapy for the acute treatment of migraine.
- Trial name
- Atenéia (NCT01390324)
- Testing
- Fixed-dose combination of naratriptan+naproxen, Naratriptan, Naproxen
- Sponsor
- Ache Laboratorios Farmaceuticos S.A.
Acute Migraine
Long-term Safety Study of BHV-3500 (Zavegepant*) for the Acute Treatment of Migraine
The purpose of this study is to evaluate the long-term safety of BHV-3500/vazegepant intranasal in the acute treatment of migraine. BHV-3500, formerly "vazegepant", is now referred to as "zavegepant" (za ve' je pant).
- Trial name
- NCT04408794
- Testing
- Zavegepant (BHV-3500)
- Where
- 67 sites in United States
- Volunteers
- 974 people
- Sponsor
- Pfizer
Migraine, Classic Migraine
Potential Impact (Benefit) of Preventative Treatment With Topamax on the Effectiveness of Axert in the Acute Treatment of Migraine
The purpose of this study is to evaluate the impact of topiramate (migraine prevention medicine) on the effectiveness of almotriptan malate (acute migraine medicine) when treating acute migraine headaches.
- Conditions
- Migraine, Classic Migraine, Common Migraine
- Trial name
- NCT00210496
- Testing
- topiramate; almotriptan malate
- Volunteers
- 406 people
- Sponsor
- Janssen-Ortho LLC
Migraine
A Study Of The Safety, Tolerability, And Pharmacokinetics Of Multiple Doses Of PF-05180999 In Healthy Adults
PF-05180999 is a novel phosphodiesterase-2 (PDE2) inhibitor. The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of multiple doses of PF-05180999 administered twice daily over 14 days.
- Trial name
- NCT01981486
- Testing
- PF-05180999 Tablets
- Volunteers
- healthy volunteers welcome
- Sponsor
- Pfizer
Migraine
Effect of Single Oral Doses of Lasmiditan When Coadministered With Single Oral Doses of Sumatriptan in Healthy Participants
This is a randomized, double-blind, three-period, cross-over study to investigate the effect of sumatriptan (Imitrex) 100 mg on the pharmacodynamics and pharmacokinetics of lasmiditan 200 mg.
- Trial name
- NCT03076970
- Testing
- lasmiditan 200 mg, Sumatriptan
- Where
- United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Migraine
The Effectiveness of Almotriptan Malate (AXERT®) 12.5 Milligrams When Taken at the Onset of Migraine Pain
The purpose of this study is to evaluate the effectiveness and safety of AXERT when treating a migraine at the onset of headache pain, as compared to treating a migraine only after the headache pain has reached at least moderate…
- Trial name
- NCT00212823
- Testing
- almotriptan malate
- Volunteers
- 1,450 people
- Sponsor
- Ortho-McNeil Neurologics, Inc.
Episodic Migraine Headache
A Multicenter Assessment of LBR-101 in High Frequency Episodic Migraine
The purpose of this study is to determine whether monthly subcutaneous administration of LBR-101 (fremanezumab) is safe and provides migraine prevention in subjects with high frequency episodic migraine.
- Trial name
- NCT02025556
- Testing
- LBR-101 High Dose, LBR-101 Low Dose
- Where
- 63 sites in United States
- Volunteers
- 297 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Migraine, With or Without Aura
An Extension Study to Evaluate the Long-Term Safety and Tolerability of Ubrogepant in the Treatment of Migraine
This study will evaluate the long-term safety and tolerability of intermittent treatment with ubrogepant for the acute treatment of migraine over 1 year.
- Trial name
- NCT02873221
- Testing
- Ubrogepant, Usual Care
- Where
- 177 sites in United States
- Volunteers
- 1,254 people
- Sponsor
- Allergan
Migraine
Study to Test an Approved Product in the Early Treatment of Migraine (0462-066)
The purpose of this study is to test the effectiveness of an approved drug in the early treatment of migraine.
- Trial name
- NCT00095004
- Testing
- MK0462, rizatriptan benzoate / Duration of Treatment: 1day
- Volunteers
- 167 people
- Sponsor
- Organon and Co
Migraine
A Study of LY3451838 in Participants With Migraine
The reason for this study is to see if the study drug LY3451838 is safe and effective in participants who have migraine that have not responded to other preventive treatments.
- Trial name
- NCT04498910
- Testing
- LY3451838
- Where
- 9 sites in United States
- Volunteers
- 38 people
- Sponsor
- Eli Lilly and Company
Migraine, Migraine With Aura
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate STS101 in the Acute Treatment of Migraine
Study STS101-002 is a randomized, double-blind, parallel group, placebo-controlled, multicenter study to evaluate the efficacy, safety, and tolerability of single doses of STS101 (dihydroergotamine nasal powder) in the acute…
- Conditions
- Migraine, Migraine With Aura, Migraine Without Aura
- Trial name
- EMERGE (NCT03901482)
- Testing
- Dihydroergotamine
- Where
- 117 sites in United States
- Volunteers
- 1,201 people
- Sponsor
- Satsuma Pharmaceuticals, Inc.
Migraine
Migraine Prevention Using ActiPatch
Chronic pain is now widely understood to be due to central sensitization, which leads to exaggerated pain perception. Migraine is no exception, since it is well known that sensitization of the trigeminovascular pain pathway can…
- Trial name
- PSWT (NCT03166046)
- Testing
- Pulsed Shortwave Therapy
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- BioElectronics Corporation